Causes & Risk Factors
A rigorous review of the established, probable, and putative risk and protective factors for Parkinson’s disease, integrating genetic, environmental, lifestyle, and mechanistic evidence.
4.1 Etiology: Idiopathic vs. Genetic PD
The etiology of PD is best conceptualized as a multifactorial, gene-environment interaction model. Approximately 85–90% of PD cases are classified as “idiopathic” — meaning no single identifiable cause is found — while 10–15% have a clearly identified monogenic cause (see Chapter 7: Genetics). However, the distinction is increasingly blurred: common genetic variants modify risk in apparently idiopathic cases, and environmental exposures likely trigger disease in genetically susceptible individuals.
4.2 Non-Modifiable Risk Factors
Age
Age is the single most powerful risk factor for PD. The prevalence doubles approximately every decade after age 60. This age-dependence likely reflects the cumulative burden of oxidative stress, mitochondrial dysfunction, impaired protein clearance (ubiquitin-proteasome and autophagy-lysosomal pathway dysfunction), and neuroinflammation over time (Collier et al., 2011, Nature Reviews Neuroscience).
Male Sex
Men have approximately 1.4–2.0 times the risk of developing PD compared to women. Estrogen appears to play a neuroprotective role, supported by epidemiological data showing that women with longer reproductive periods (later menopause, earlier menarche) have somewhat lower PD risk (Simon et al., 2020, Movement Disorders).
Genetics
Having a first-degree relative with PD increases risk approximately 2–3 fold. Monogenic mutations (LRRK2, SNCA, PRKN, PINK1, DJ-1, GBA1) account for familial clustering in identified cases. See the dedicated Genetics chapter for comprehensive treatment of all implicated genes.
Ethnicity
The LRRK2 G2019S mutation has a prevalence of approximately 1% in sporadic Ashkenazi Jewish PD and ~40% in familial North African Arab PD. GBA1 mutations are more prevalent in Ashkenazi Jewish populations. These genetic-ethnic interactions contribute to population-specific risk profiles.
4.3 Environmental Risk Factors
| Factor | Direction | Relative Risk / Odds Ratio | Proposed Mechanism |
|---|---|---|---|
| Pesticide exposure (paraquat, rotenone, organochlorines) | ↑ Risk | RR 1.5–2.2 | Mitochondrial complex I inhibition; oxidative stress; dopaminergic neurotoxicity |
| Rural living / well water | ↑ Risk | RR ~1.5 | Higher pesticide and herbicide exposure |
| Traumatic brain injury (TBI) | ↑ Risk | RR 1.5–3.5 | Neuroinflammation; alpha-synuclein release; dopaminergic vulnerability |
| Heavy metal exposure (manganese, lead) | ↑ Risk | Variable | Mitochondrial dysfunction; oxidative stress (manganese especially for manganism) |
| Trichloroethylene (TCE) | ↑ Risk | RR ~6.1 | Mitochondrial complex I inhibition; widely used industrial solvent and common groundwater contaminant |
| Air pollution (PM2.5, NO₂) | ↑ Risk | RR ~1.3 per 5 µg/m³ | Neuroinflammation via olfactory and vascular routes |
| Cigarette smoking | ↓ Risk | RR ~0.5 | Nicotinic receptor stimulation; MAO inhibition by tobacco compounds; reduced competing mortality confounding |
| Caffeine/coffee consumption | ↓ Risk | RR ~0.7 | Adenosine A2A receptor antagonism; neuroprotective in animal models |
| Physical activity | ↓ Risk | RR ~0.7 | BDNF upregulation; reduced neuroinflammation; neuroprotection |
| Ibuprofen (regular use) | ↓ Risk | RR ~0.7 | Anti-inflammatory effects; inhibition of neuroinflammatory cascades |
| Uric acid (hyperuricemia) | ↓ Risk | RR ~0.7 | Potent antioxidant; inverse association replicated in multiple cohort studies |
| Type 2 diabetes | ↑ Risk | RR ~1.4 | Insulin resistance, neuroinflammation, mitochondrial dysfunction |
| Appendectomy | ↓ Risk (weak) | RR ~0.8 | Appendix as reservoir of alpha-synuclein; controversial |
4.4 The Gut-Brain Axis & Environmental Triggers
Converging evidence points to the gastrointestinal tract as a potential site of PD initiation. The “gut-first” hypothesis, supported by Braak’s staging model and epidemiological data, proposes that environmental triggers (possibly ingested toxins, pathogens, or microbial dysbiosis) initiate alpha-synuclein aggregation in the enteric nervous system, which then propagates retrogradely via the vagus nerve to the brainstem and midbrain (Hawkes et al., 2007, Movement Disorders). Supporting this hypothesis: vagotomy (particularly truncal, performed for peptic ulcer disease before the H. pylori era) is associated with modestly reduced PD risk in some but not all studies (Svensson et al., 2015, Annals of Neurology). A complementary “brain-first” hypothesis proposes that in other patients, pathology initiates in the CNS. Both pathways may coexist, with heterogeneous prodromal presentations reflecting the site of initiation.
References: Collier et al. (2011) Nat Rev Neurosci; Hawkes et al. (2007) Mov Disord; Ross et al. (2008) Ann Neurol; Simon et al. (2020) Mov Disord; Svensson et al. (2015) Ann Neurol.
Navigation: ← Symptoms | Diagnosis →